Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
As a result the target price of 29 € shows a positive potential of 30.63% compared to the current price of 22.2 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | - | 7.767% | 4.717% | 25.424% | 2.778% | -34.706% | -60.357% |
| Rockwell Medical Inc. | -0.960% | 13.833% | 4.222% | -59.381% | 22.247% | -21.981% | -91.258% |
| Twist Bioscience Corp | 3.320% | 9.837% | 11.778% | -30.567% | 9.048% | 32.187% | -77.832% |
| Vericel Corp. | -0.570% | 14.570% | 6.135% | -39.298% | 9.494% | 54.464% | 22.046% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat